Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 5;20(18):4350.
doi: 10.3390/ijms20184350.

Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis-A Network Meta-Analysis of 36 Randomized Controlled Trials

Niels Graudal  1 , Benjamin Skov Kaas-Hansen  2   3 , Louise Guski  2 , Thorbjørn Hubeck-Graudal  4 , Nicky J Welton  5 , Gesche Jürgens  2
Affiliations
Review

Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis-A Network Meta-Analysis of 36 Randomized Controlled Trials

Niels Graudal et al. Int J Mol Sci. .

Abstract

The effect of five approved tumour necrosis factor inhibitors (TNFi: infliximab, etanercept, adalimumab, certolizumab, and golimumab) on joint destruction in rheumatoid arthritis (RA) have been compared versus methotrexate (MTX) in randomized controlled trials (RCTs) but have not been compared directly to each other or to an otherwise untreated placebo control. The present analysis compares effects of standard doses, high doses, and low doses of TNFis on radiographic joint destruction in RA and relate these effects to MTX and placebo by means of a Bayesian network meta-analysis. We identified 31 RCTs of the effect of TNFis on joint destruction and 5 RCTs with controls, which indirectly could link otherwise untreated placebo controls to the TNFi treatments in the network. The previously untested comparison with placebo was performed to estimate not only the effect relative to another drug, but also the absolute attainable effect. Compared to placebo there was a highly significant inhibitory effect on joint destruction of infliximab, etanercept, adalimumab, certolizumab, and golimumab, which was about 0.9% per year as monotherapy and about 1.2% per year when combined with MTX. Although significantly better than MTX and placebo, golimumab seemed inferior to the remaining TNFis. There was no difference between original reference drugs (Remicade, Enbrel) and the almost identical copy drugs (biosimilars).

Keywords: joint destruction; network meta-analysis; randomized controlled trial; rheumatoid arthritis; tumor necrosis factor (TNF) inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Flow diagram of search.
Figure 2
Figure 2
Network of treatments investigated in included studies. (Ad20x2Mt (adalimumab 20 mg/1 week plus MTX); AdMt (adalimumab 40 mg/2 weeks plus MTX); Ad (adalimumab 40 mg/2 weeks); Cz4Mt (certolizumab 400 mg/2 weeks plus MTX); Cz1Mt (certolizumab 100 mg/2 weeks plus MTX); Cz2Mt (certolizumab 200 mg/2 weeks plus MTX); Cz2 (certolizumab 200 mg/2 weeks); Su (sulfasalazine); Pl (placebo); In20Mt (infliximab 20 mg/kg/8 weeks plus MTX); In10Mt (infliximab 10 mg/kg/8 weeks plus MTX); In6Mt (infliximab 6 mg/kg/8 weeks plus MTX); In3Mt (infliximab 3 mg/kg/8 weeks plus MTX); SB2 (biosimilar infliximab); CTP (biosimilar infliximab); SB4 (biosimilar etanercept); Et25Mt (etanercept 25 mg/1 week plus MTX); Et50Mt (etanercept 50 mg/1 week plus MTX); Et50 (etanercept 50 mg/1 week); Et20 (etanercept 20 mg/1 week); Go5Mt (golimumab 50 mg/4 weeks plus MTX); Go10 (golimumab 100 mg/4 weeks); Go10Mt (golimumab 100 mg/4 weeks plus MTX); Go13Mt (golimumab 130 mg/4 weeks plus MTX)).
See this image and copyright information in PMC

References

    1. Lim H., Lee S., Lee H., Lee J., Son J., Shin W., Heo Y.S. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis. Int. J. Mol. Sci. 2018;19:768. doi: 10.3390/ijms19030768. - DOI - PMC - PubMed
    1. Hassell A.B., Davis M.J., Fowler P.D., Clarke S., Fisher J., Shadforth M.F., Jones P.W., Dawes P.T. The relationship between serial measures of disease activity and outcome in rheumatoid arthritis. Q. J. Med. 1993;86:601–607. - PubMed
    1. Graudal N., Tarp U., Jurik A.G., Galløe A.M., Garred P., Milman N., Graudal H.K. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: Long-term course and association to radiographic progression. J. Rheumatol. 2000;27:47–57. - PubMed
    1. Graudal N. The natural history and prognosis of rheumatoid arthritis: Association of radiographic outcome with process variables, joint motion and immune proteins. Scand. J. Rheumatol. Suppl. 2004;118:1–38. doi: 10.1080/03009740310004847. - DOI - PubMed
    1. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–1110. doi: 10.1016/S0140-6736(94)90628-9. - DOI - PubMed

MeSH terms

Substances